The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Open accessAbstract
BACKGROUNDLipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODSWe conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L Rx , referred to here as APO(a)-L Rx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.The lipoprotein(a) level was measured with an isoform-independent assay.The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses). RESULTSThe median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter.Administration of APO(a)-L Rx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001).There were no significant differences between any APO(a)-L Rx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms.The most common adverse events were injection-site reactions.CONCLUSIONS APO(a)-L Rx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the same time, pelacarsen was well tolerated. Only injection site reactions were more frequently observed in the treatment group.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dose-dependent manner by up to − 80% from baseline [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“Lp(a) has been identified as an independent risk marker for CVD as it exerts pro-atherogenic, pro-inflammatory, and pro-thrombotic effects which may play a critical role in the pathogenesis of atherosclerosis [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationvan der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Self-citationLipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Lipoprotein(a) Concentrations Are Independent of Polygenic Score for Coronary Artery Disease
Trinh, M. N., Pournamdari, A. B., Small, A., Peloso, G. M., Patel, A. P., & Natarajan, P. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100800 · Cited by 5
Кучай, А. А., Липин, А. Н., Груздев, Н. Н., Геннадьевич, Б. А., Ширан, В. А., & Курач, М. (2023) · Russian Biomedical Research · doi:10.56871/rbr.2023.32.30.007 · Cited by 5
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
Ogieuhi, I. J., Callender, K., Odukudu, G.-D. O., Obi, E. S., Muzofa, K., Babalola, A. E., Ugiomoh, O. M.-A., Umenzeakor, K. H., Akingbola, A., Ayoson, C. O., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00682-w · Cited by 5
Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches
Zhang, Z., Peng, B., Nuranmubieke, A., Xu, Y., Liu, Y., Tu, T., Lin, Q., Wang, C., Liu, Q., & Xiao, Y. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.102301 · Cited by 6
The Role of Lipoprotein(a) in the Progression of Aortic Stenosis
Sherrill, C., Ehrhardt-Humbert, L. C., & Salem, D. N. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.02.024 · Cited by 5
Wu, C., Hou, C., Zhao, W., Li, C., Chu, X., Wu, L., Wang, Y., Zhou, C., Liu, G., Zhang, W., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00579 · Cited by 5
Impact of Lipoprotein(a) Levels on Perioperative Outcomes in Cardiac Surgery
Heinisch, P. P., Mihalj, M., Huber, M., Schefold, J. C., Hartmann, A., Walter, M., Steinhagen‐Thiessen, E., Schmidli, J., Stüber, F., Räber, L., et al. (2021) · Cells · doi:10.3390/cells10112829 · Cited by 5
Self-citationAssociation of various lipid parameters with premature coronary artery disease in men
Tyurina, A. V., Афанасьева, О. И., Александровна, К. Е., Tmoyan, N. A., Андреевна, Р. О., Владиславович, Е. М., & Pokrovsky, S. N. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5058 · Cited by 5
Reuser, A., Köenig, W., & Laufs, U. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2701 · Cited by 5
Parhofer, K. G. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01536-8 · Cited by 5
Frequency of lipoprotein(a) measurements in patients with or at risk of cardiovascular disease
Upadhyaya, B., Wang, Y., Bruckel, J., & Block, R. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.09.009 · Cited by 5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
Barrios, V., Escobar, C., Anguita, M. P., Arrarte, V., Ruíz, R. C., Cosı́n-Sales, J., Cabello, M. I. E., Martínez, J. M. G., Guijarro, C., Mostaza, J. M., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2021.02.006 · Cited by 5
Fernando, P. M. S., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2352129 · Cited by 5
Current perspectives on Lp(a)-lowering therapies: Who may benefit?
Nicholls, S. J., & Nelson, A. J. (2025) · Kardiologia Polska · doi:10.33963/v.phj.106327 · Cited by 5
Emerging pharmacological strategies in lipoprotein(a) reduction
Mansoor, T., Ismayl, M., Parikh, S. S., Nambi, V., Virani, S. S., Mehta, A., Jia, X., & Minhas, A. M. K. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2524791 · Cited by 4
Nasoufidou, A., Glava, A., Mavridou, M., Stachteas, P., Karagiannidis, E., Patoulias, D., Kassimis, G., Fragakis, N., & Kavga, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176018 · Cited by 4
Legget, M. E., Earle, N. J., Poppe, K., Bradbury, K. E., Pilbrow, A. P., Logue, G., Choi, Y. C., Devlin, G., Gladding, P. A., Grey, C., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120516 · Cited by 4
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 4
Safety of low lipoprotein(a) levels: the FOURIER trial
Gencer, B., Giugliano, R. P., Ran, X., Mach, F., Stroes, E. S. G., Gouni‐Berthold, I., Češka, R., Владиславович, Е. М., Jukema, J. W., Jensen, H. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag398 · Cited by 4
Self-citationLipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes
Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230601155001 · Cited by 5
Tada, H., Kojima, N., Yamagami, K., Takeji, Y., Sakata, K., Usui, S., Kawashiri, M., & Takamura, M. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.120 · Cited by 4
Li, L., Hu, Z., Wu, L., WU, L., Liu, L., Zhou, L., Peng, X., Xu, M., Zhang, T., Zhao, M., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.08.001 · Cited by 4
Brandt, E. J., Kirch, M., Patel, N., Chennareddy, C., Murthy, V. L., & Goonewardena, S. N. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101016 · Cited by 4
Schatoff, D., Jung, I. Y., & Goldberg, I. J. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.009 · Cited by 5
The era of targeted therapy for hyperlipidemia
Чубыкина, У. В., Tyurina, A. V., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6038 · Cited by 6
Lipoprotein(a) and Effects of Diet: Time for Reassessment
Enkhmaa, B., & Berglund, L. (2025) · Nutrients · doi:10.3390/nu17101714 · Cited by 5
AKCEA-APO(a)-LRx lowers Lp(a) levels in patients
Fernández-Ruíz, I. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0336-5 · Cited by 4
Lipoprotein(a)—When to Screen and How to Treat
Patel, N., Mittal, N., Choubdar, P. A., & Taub, P. R. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00698-8 · Cited by 4
Serum Lipoprotein(a) and 3-Year Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Corpataux, N., Hochholzer, W., Valina, C. M., Ferenc, M., Löffelhardt, N., Westermann, D., Neumann, F., & Nührenberg, T. G. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101362 · Cited by 4
Zhao, L. Y., Sun, L., Zhang, Z., Yang, K., Li, Z., Wang, M., Zeng, Y., Zhou, X., & Yang, W. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01901-4 · Cited by 4
Lipoprotein(a): Behandlung eines unterschätzten kardiovaskulären Risikomarkers
Langhammer, R., & Laufs, U. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1164-6087 · Cited by 4
The next chapter of prevention: from LDL-cholesterol to lipoprotein(a) and triglycerides
Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa552 · Cited by 4
Mullan, B. A., Chan, D. C., Charlesworth, J., Moullin, J. C., Schultz, C. J., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000609 · Cited by 4
Yao, Y., Liu, J., Wang, B., Zhou, Z., Lu, X., Huang, Z., Deng, J., Yang, Y., Tan, N., Chen, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.817442 · Cited by 4
New and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 4
Nedunchezhian, S., Reddy, T. K., Wegener, M., O’Connell, S. S., & Ferdinand, K. C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100179 · Cited by 4
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome
Steg, P. G., Szarek, M. J., Valgimigli, M., Islam, M. S., Zeiher, A. M., Bhatt, D. L., Bittner, V., Chiang, C., Díaz, R., Goodman, S. G., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.018 · Cited by 4
The cardiovascular benefit of Lp(a) reduction: not there yet
Pirillo, A., & Catapano, A. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa842 · Cited by 4
Zhu, L., Fang, Y., Gao, B., Jin, X., Zheng, J., Yin, H., & Huang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2014611/v1 · Cited by 4
Emerging Lp(a)-Lowering therapies: Is muvalaplin a potential breakthrough?
Afzal, Z., Hira, S., & Cao, H. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200262 · Cited by 4
Lipoprotein(a) and aortic stenosis: Practical insights
Dimitriadis, K. S., Kyriakoulis, K. G., Pyrpyris, N., Beneki, E., Kamperidis, V., Κόλλιας, Α., Cenko, E., Aznaouridis, K. A., Aggeli, K. D., & Tsioufis, K. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104124 · Cited by 3
Lipoprotein(a) in Japanese Patients With Cardiovascular Disease
Yoshida, H., Kroes, M., Sakai, Y., Takahashi, Y., Yamanaka, Y., Crawford, B., & Ako, J. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.08.017 · Cited by 3
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 4
Lipoprotein(a) and long-term structural valve degeneration of aortic bioprostheses
Boute, M., Salembier, P., Pouleur, A., Pasquet, A., Gerber, B. L., Azevedo, D. D., Gruson, D., de Kerchove, L., Kefer, J., Beauloye, C., et al. (2025) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaf320 · Cited by 3
Obicetrapib: A Novel Cholesterol Ester Transfer Protein Inhibitor
Maalizadeh, K., Parikh, M. A., Hunt, C. R., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001136 · Cited by 3
Lipoprotein(a) Is Associated With Increased Risk of Abdominal Aortic Aneurysm
Sharma, P., Judy, R., Yuan, S., Gellatly, C., Saxby, K. L., Rader, D. J., Bown, M. J., Levin, M. G., & Damrauer, S. M. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101457 · Cited by 3
Hu, J., Wang, J., Zhang, H., Jiang, Y., Deng, L., Long, E., & Liu, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1758366 · Cited by 3
Cheng, C.-Y., Wu, Y., Yeh, C., Huang, P., Hsu, C.-Y., Lin, T.-H., Wang, Y.-C., Wang, C., Wang, C., Huang, Y., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.03.073 · Cited by 3
Lowering of Lipoprotein(a) with Olpasiran
Amo-Tweneboah, C., & Kaur, G. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x428489260113103704 · Cited by 6
Genetic factors contributing to atherosclerosis
Raddatz, M. A., Allayee, H., & Lusis, A. J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001286 · Cited by 4
Knowledge, Use, and Barriers in Dyslipidemia Management: A Cross-Sectional Survey of Clinicians
Mesquita-Lousada, A., Barbosa, A., Silva, J., D’Oria, M., Silva, D. S., Andrade, J. P., Ribeiro, H., & Rocha-Neves, J. P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072745 · Cited by 3
The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention
Verpalen, V. A., Coerkamp, C. F., Malkasian, S., Gaillard, E. L., Beverloo, C. Y. Y., Ibrahim, S., van de Vijver, W. R., Claessen, B. E. P. M., Knaapen, P., Takx, R. A. P., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag243 · Cited by 4
Self-citationHemelrijk, K. I., Delewi, R., Mehran, R., & Boekholdt, S. M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120731 · Cited by 5
Alotaibi, R. M., Al-Salmi, R. H., Shosho, R. O., Alzahrani, Y. A., & Harbi, M. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135233 · Cited by 3
Li, Y., Song, W., Huan, C., Xu, K., Sun, J., Zhen, X., Ouyang, H., Tang, H., Fan, Q., Zhi, W., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109089 · Cited by 3
Rubio‐Serrano, J., Gullón, A., & Fernández, C. S. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0090 · Cited by 3
Kršek, A., Batičić, L., & Tokmadžić, V. S. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030012 · Cited by 4
Loewenstein, I., Lichtenstein, D., Goldiner, I., Ben‐Shoshan, J., Halkin, A., Konigstein, M., Banai, S., Arbel, Y., Finkelstein, A., & Steinvil, A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101264 · Cited by 3
Li, J., Yan, K., Zhu, P., Tang, X., Yang, Y., Gao, R., Yuan, J., & Zhao, X. (2024) · Clinical Cardiology · doi:10.1002/clc.70025 · Cited by 3
Li, J., Ma, B., Fang, Q., Wang, J., Sun, Y., Ding, H., & Wang, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02467-z · Cited by 3
Gomes, L. L. A., Faden, D. F., Xie, L., Chambers, S., Stone, C. J., Werth, V. P., & Williams, K. J. (2025) · Lupus Science & Medicine · doi:10.1136/lupus-2024-001160 · Cited by 3
Looking for lipoprotein(a) in youngsters: a call to action
Bilato, C., Zuin, M., & Rigatelli, G. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001717 · Cited by 3
Renkens, M. P. L., Tsai, T., Revaiah, P. C., Kageyama, S., Reiber, J. H. C., de Winter, R. J., Grundeken, M. J., Nurmohamed, N. S., Stroes, E. S. G., Garg, S., et al. (2025) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2025.07.003 · Cited by 3
Self-citationOgunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis
Polkinghorne, M., Badi, I., Baragetti, A., Chauhan, J. S., Xie, C., Wahome, E., Akoumianakis, I., Foran, D., Patel, P., de Araujo, E., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322924 · Cited by 5
Emerging therapies targeting lipoprotein(a): Pharmacologic advances and future directions
Perez, A. D., Simpson, R. J., Komé, A. M., & Lopez, S. T. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103695 · Cited by 3
Krieter, D. H., Jeyaseelan, J., Rüth, M., Lemke, H., Wanner, C., & Drechsler, C. (2021) · Artificial Organs · doi:10.1111/aor.13944 · Cited by 3
Mehtarian, E., Musavi, H., Hashemi‐Soteh, M. B., Mokhtari, H., Bagheri, B., & Zargari, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101350 · Cited by 3
Huang, Y., Cheng, Y., Wu, V. C., Lin, C., Kao, Y., Chu, P., & Lin, Y. (2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20211225a · Cited by 3
High levels of lipoprotein(a) – assessment and treatment
Svilaas, T., Klemsdal, T. O., Bogsrud, M. P., Græsdal, A., Vesterbekkmo, E. K., Asprusten, E. A., Langslet, G., & Retterstøl, K. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0800 · Cited by 3
Physiological Roles and Functions of Lipoprotein(a)
Safiullah, Z. N., Leucker, T. M., Jones, S. R., & Toth, P. P. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_8 · Cited by 3
Šuran, D., Završnik, T., Kokol, P., Kokol, M., Sinkovič, A., Naji, F. H., Završnik, J., Vošner, H. B., & Kanič, V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093220 · Cited by 3
Wang, Z., & Li, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01926-9 · Cited by 3
Wang, K., Wang, W., Niu, J., Liu, X., Han, H., Shen, H., Sun, Y., Gao, W., & Ge, H. (2024) · Angiology · doi:10.1177/00033197241239688 · Cited by 4
Law, H. G., Myagmarsuren, M., Bang, H., Zhang, W., Lefevre, M., Berglund, L., & Enkhmaa, B. (2025) · Nutrients · doi:10.3390/nu17030426 · Cited by 3
Determination of the biological variation and reference change value of lipoprotein (a)
Antwi, K., DOWNIE, P. F., & Mbagaya, W. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251324063 · Cited by 3
Distinct lipoprotein contributions to valvular heart disease: Insights from genetic analysis
Luo, D., Björnson, E., Wang, X., Zhang, B., Xu, C., Guan, Y., Xiang, S., Borén, J., Hao, X., & Chen, J. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133218 · Cited by 3
Zhang, J., Sang, J., Jiang, Y., Yi, Z., Zhang, J., Liu, X., Qiu, H., Zhao, K., Sun, H., Yang, Y., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1434745 · Cited by 3
Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches
Razavi, A. C., Hong, J., & Bhatia, H. S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02255-2 · Cited by 3
Lippi, G., & Targher, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0076 · Cited by 3
Lipoprotein(a), the rediscovered risk factor, or how to get “back to the future”
Sabouret, P. F., Angoulvant, D., & Ray, K. K. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.03.008 · Cited by 3
Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients
Clark, D., Puri, R., & Nissen, S. E. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1833716 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3
Location of recurrent cardiovascular events and anticardiolipin antibodies
Galán‐González, J., Rico‐Martín, S., García, J. F. C., Antón, J., Ramírez-Moreno, J. M., Álvarez, L. R., Muñoz-Torrero, J. F. S., & for FRENA Investigators (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13533 · Cited by 3
Lipoprotein (a): Aus kardiologischer Sicht zu wenig beachtet?
Wienbergen, H., Rühle, S., Osteresch, R., & Hambrecht, R. (2021) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2021.04.16.05 · Cited by 3
Residual Cardiovascular Risk Factors in Dyslipidemia
Nguyen, V. S., Tran, X. T., Vo, T. D., & Le, Q. T. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100046 · Cited by 3
Cholesterol transport in blood, lipoproteins, and cholesterol metabolism
Auley, M. T. M., & Morgan, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00025-0 · Cited by 3
Tsimikas, S., Bhatia, H. S., & Erlinge, D. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.06.005 · Cited by 3
Self-citationEmerging therapies in dyslipidaemias
Catapano, A. L. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107229 · Cited by 3
Metabolism of lipoprotein(a): new findings, implications and outstanding issues
Chan, D. C., & Watts, G. F. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000678 · Cited by 3
Capoulade, R., & Cariou, B. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.009 · Cited by 3
Lipoprotein(a) Cholesterol Masquerading as Low-Density Lipoprotein Cholesterol
Paré, G., Chong, M., & Mohammadi‐Shemirani, P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.01.014 · Cited by 3
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments
Polychronopoulos, G., Papagiannis, A., & Τζιόμαλος, Κ. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174524 · Cited by 3
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Nissen, S. E., Návar, A. M., & Krege, J. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2507989 · Cited by 3
Klose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
Self-citationThe need for national and international registries of patients with elevated lipoprotein(a)
Kramer, A. I., Iatan, I., & Brunham, L. R. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000982 · Cited by 2
Röseler, T., Kayser, D., Schlieper, G., & Bernhardt, W. M. (2025) · Journal of Clinical Apheresis · doi:10.1002/jca.70020 · Cited by 2
Cholesterol, Cognition, and Controversy: A Case of Mood Disturbance on Repatha
Conte, M., Mao, B., Tahir, S., Rodriguez, A., & Hussain, S. T. (2025) · Cureus · doi:10.7759/cureus.87165 · Cited by 2
Metadata
- Authors
- Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L.
- Affiliations
- University of Cologne (DE)
- From the Divisions of Cardiovascular Medicine (S.T.) and Endocrinology and Metabolism (J.L.W.), University of California, San Diego, La Jolla, and Ionis Pharmaceuticals, Carlsbad (S.T., S.X., N.J.V.) — both in California; Akcea Therapeutics, Boston (E.K.-P., J.G., L.O.); Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany (I.G.-B.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); Excel Medical Clinical Trials, Boca Raton, FL ...
- Oregon Health & Science University (US)
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 244-255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2997944188
- Semantic Scholar
- 725c405ccc1ec3726f9ba922da158107891d134f
- Cited by
- 1,094
- References
- 28
- Citations by year
- 2026: 204 · 2025: 176 · 2024: 156 · 2023: 149 · 2022: 159 · 2021: 153 · 2020: 96
- FWCI
- 127.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), antisense oligonucleotides, cardiovascular disease, injection site reactions, genetic risk factors
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Oligonucleotides, Risk Factors, Least-Squares Analysis, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
